Zion Market Research has published a new report titled “Opioid Use Disorder Market by Drug (Buprenorphine, Methadone and Naltrexone): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025”.
According to the report, global demand for Opioid Use Disorder Market was valued at approximately USD 1500.39 Million in 2018, and is expected to generate revenue of around USD 2853.57 Million by end of 2025, growing at a CAGR of around 9.69% between 2018 and 2025.
Request Free Sample is Available @ https://www.zionmarketresearch.com/sample/opioid-use-disorder-market
Opioids, which are medicinally used for pain relief, have debilitating effects on the analgesic and central nervous system as well as euphoria potential. Opioid use disorder (OUD) may include misuse of prescription opioid drugs, use of diverted opioid drugs, or use of heroin that is illegally obtained. Opioid use disorder is usually a chronic, recurring condition associated with levels of morbidity and mortality significantly higher.
The rising number of patients with opioid-related addiction, increased government efforts and increased support from NGOs and agensis are key factors driving the market for opioid use disorder care. The NGOs organize various programs and initiatives with the help of government organizations and many others to increase awareness of the clinical ill-effects of Opioid abuse. The aim of these programs is to eliminate illicit drug use in federal workplaces and lead to drug-free all workplaces. Nevertheless, the factors that limit the growth of this market are individuals ‘ inability to pursue treatment modalities and the discontinuation of behavioral treatments that contribute to relapse. Government initiatives and funding are important tools for this sector.
The market for Opioid Use Disorder is segmented based on drugs and region. Based on Drugs, the market is segmented into Buprenorphine, Methadone and Naltrexone. Buprenorphine is further classified into Bunavail, Sublocade, Suboxone, Zubsolv and Others. The major revenue generating segment in 2018 was buprenorphine. The most widely prescribed drugs for opioid use disorder include buprenorphine / naloxone sublingual tablet, branded suboxone and buprenorphine sublingual tablet. Because of its excellent clinical profile, Suboxone Film is the most prescribed drug on the opioid use disorder market. High effectiveness in addiction treatment, low potential for abuse & relatively slight adverse effects and favorable type exposure are factors that can be contributed to this drug’s high acceptance.
Geographic segmentation includes the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. In 2018, North America was the largest revenue-generating market and is expected to show the same pattern over the forecast period. The opioid epidemic of the U.S. and Canada is one of the major contributing factors to the largest market share in North America. A variety of measures are being pursued by governments to tackle the crisis.
Some of the players included in Opioid Use Disorder market are Indivior, Alkermes, Titan Pharmaceuticals, Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, and Omeros amongst others.
The report segments global Opioid Use Disorder market as follows:
Global Opioid Use Disorder Market: Drug Segment Analysis
Global Opioid Use Disorder Market: Regional Segment Analysis
To view TOC of this report is available upon request @ https://www.zionmarketresearch.com/toc/opioid-use-disorder-market